Scarica l'app Stockscreener
45.82
1.20%
0.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$45.30
Aprire:
$45.88
Volume 24 ore:
7.42M
Relative Volume:
0.62
Capitalizzazione di mercato:
$17.95B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-5.2486
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-11.62%
1M Prestazione:
+47.17%
6M Prestazione:
+40.36%
1 anno Prestazione:
+12.58%
Intervallo 1D:
$45.72
$47.85
Intervallo di 1 settimana:
$43.55
$51.18
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
45.95 | 17.70B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.07 | 121.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.10 | 78.94B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.54 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.49 | 46.18B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
349.62 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
U.S. vaccine hesitancy could impact investment - Axios
Moderna, Inc. $MRNA Shares Sold by Federated Hermes Inc. - MarketBeat
This Stock Is Already Up 58% This Year. Is It a Buy? - Finviz
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating - marketscreener.com
Moderna (MRNA) Leads Healthcare Stocks with Impressive Gains - GuruFocus
Top performing healthcare stocks in the past month (MRNA:NASDAQ) - Seeking Alpha
Moderna (NASDAQ:MRNA) Coverage Initiated at Barclays - MarketBeat
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More - BioSpace
Analyst Calls: Can Moderna Inc continue delivering strong returns2025 Year in Review & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Oncolytics Biotech Strengthens Leadership for Oncology Trials - Intellectia AI
US Stocks Recap: What are the future prospects of Moderna IncBuy Signal & Weekly High Conviction Ideas - baoquankhu1.vn
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - The Motley Fool
Moderna (MRNA) stock slips; Feb. 13 earnings call is the next catalyst for the share price - TechStock²
Behind the Scenes of Moderna's Latest Options Trends - Benzinga
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 - ACCESS Newswire
Aug Momentum: Is Moderna Inc a momentum stockJuly 2025 Levels & Capital Protection Trading Alerts - baoquankhu1.vn
Moderna shifts focus in response to US vaccine skepticism - medwatch.com
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - lansingstatejournal.com
Promising Biotech Stocks To Follow TodayJanuary 25th - MarketBeat
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities - hattiesburgamerican.com
Hecla Mining, Moderna, And Micron Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 19-Jan. 23): Are the Others in Your Portfolio?First Majestic Silver (NYSE:AG), Coeur Mining (NYSE:CDE), Hecla Mining (NYSE:HL), Iamgold (NYSE:IAG) - Benzinga
Aug PostEarnings: Is Moderna Inc a turnaround storyMarket Trend Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug PreEarnings: Will TriSalus Life Sciences Inc benefit from rate cutsJuly 2025 Movers & Reliable Intraday Trade Alerts - baoquankhu1.vn
Moderna downsizing investments in late-stage vaccine trials amid U.S. skepticism (Video) - Social News XYZ
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk - TechStock²
Why Moderna (MRNA) Is Up 16.4% After Five-Year Data On Personalized Melanoma mRNA Therapy - Yahoo Finance
Moderna, Inc. $MRNA Shares Sold by Baillie Gifford & Co. - MarketBeat
Moderna downsizing investments in late-stage vaccine trials amid U.S. skepticism - Yahoo
Moderna Options Spot-On: On January 23rd, 191.29K Contracts Were Traded, With 974.59K Open Interest - 富途资讯
The Globe’s stars and dogs for the week - The Globe and Mail
Moderna's Growth Strategy Seen as Reassuring Investors -- Market Talk - 富途资讯
Healthcare Sector Declines 1.2%, Moderna Falls 7.2% Amidst Market Weakness - Intellectia AI
Promising Biotech Stocks Worth WatchingJanuary 23rd - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap DownHere's What Happened - MarketBeat
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg - BioSpace
Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna… - marketscreener.com
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - sj-r.com
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials - TechStock²
Intel, GE Aerospace, Moderna, Abbott, Mobileye, McCormick, and More Stock Movers - Barron's
Moderna (NASDAQ:MRNA) Trading Up 10.2%Time to Buy? - MarketBeat
Moderna Stock Soars. Why a Cancer Vaccine Study Has Sparked a Rally. - Barron's
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally - FinancialContent
Moderna (MRNA) Halts Phase 3 Vaccine Development Amid U.S. Regulatory Challenges - GuruFocus
Moderna (MRNA) Sees Bullish Activity with Increased Options Trading - GuruFocus
Moderna is curbing investment in vaccine trials due to US backlash - MSN
Moderna cutting R&D on vaccines amid U.S. pushback: CEO (MRNA) - Seeking Alpha
Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV - kfgo.com
Moderna-Merck mRNA Vaccine Slashes Melanoma Recurrence by 49% at 5 Years - WebProNews
Biotech Stocks To Keep An Eye OnJanuary 22nd - MarketBeat
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):